Analysts Are Bullish on Top Healthcare Stocks: Arcutis Biotherapeutics (ARQT), Kymera Therapeutics (KYMR)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arcutis Biotherapeutics (ARQT – Research Report), Kymera Therapeutics (KYMR – Research Report) and Becton Dickinson (BDX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arcutis Biotherapeutics (ARQT)
In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Arcutis Biotherapeutics, with a price target of $34.00. The company’s shares closed last Friday at $26.97.
According to TipRanks.com, Tsao is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcutis Biotherapeutics with a $33.89 average price target, a 21.3% upside from current levels. In a report issued on February 26, TD Cowen also maintained a Buy rating on the stock with a $35.00 price target.
See the top stocks recommended by analysts >>
Kymera Therapeutics (KYMR)
Barclays analyst Eliana Merle maintained a Buy rating on Kymera Therapeutics today and set a price target of $133.00. The company’s shares closed last Friday at $91.35.
According to TipRanks.com, Merle is a 4-star analyst with an average return of
Kymera Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $119.72, which is a 29.9% upside from current levels. In a report issued on February 27, TipRanks – Google also upgraded the stock to Buy with a $103.00 price target.
Becton Dickinson (BDX)
Barclays analyst Matt Miksic maintained a Buy rating on Becton Dickinson today and set a price target of $202.00. The company’s shares closed last Friday at $176.48.
According to TipRanks.com, Miksic is a 4-star analyst with an average return of
Becton Dickinson has an analyst consensus of Moderate Buy, with a price target consensus of $191.64, a 9.3% upside from current levels. In a report issued on February 26, TipRanks – xAI also upgraded the stock to Buy with a $201.00 price target.
